Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Kyntra Bio, formerly known as FibroGen Inc., is based in SAN FRANCISCO.
| Revenue (Most Recent Fiscal Year) | $6.44M |
| Net Income (Most Recent Fiscal Year) | $183.45M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.80 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -761.59% |
| Net Margin (Trailing 12 Months) | 2199.13% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -36.71% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.61 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.48 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 1.19 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-7.60 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-3.74 |
| Earnings per Share (Most Recent Fiscal Year) | $-12.77 |
| Diluted Earnings per Share (Trailing 12 Months) | $40.46 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 4.05M |
| Free Float | 3.97M |
| Market Capitalization | $28.30M |
| Average Volume (Last 20 Days) | 7693.50 |
| Beta (Past 60 Months) | 1.03 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.98% |
| Percentage Held By Institutions (Latest 13F Reports) | 72.71% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |